Yudhistira Persaud
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,225 of the $126,555 with a category attached, or 92.6%. GSK accounts for 99.6% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $56,791, more than ten times the $168 reported in 2019. Among allergy clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1081.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$126K
- AstraZeneca$271
- Sanofi$107
- Blueprint Medicines Corporation$52
- AbbVie$48
- Dynavax Technologies Corporation$34
- plus $33 from 1 others
Across 42 payments — averaging $3648.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$91K
- Teva Pharmaceuticals USA, Inc.$62K
What the payments were for
- Consulting fees$3,2503%
- Speaking & faculty fees$117,22593%
- Travel & lodging$1,5341%
- Food & beverage$4,5464%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $126,010 |
| AstraZeneca | 7 | $271 |
| Sanofi | 6 | $107 |
| Blueprint Medicines Corporation | 1 | $52 |
| AbbVie | 2 | $48 |
| Dynavax Technologies Corporation | 1 | $34 |
| Amgen | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$122,055
How this compares
$126,555 in reported general payments places this provider in the 95th percentile of 92 allergy providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 49 | $175,765 |
| TezspireTezepelumab-Ekko | 31 | $138,183 |
| FasenraBenralizumab | 16 | $92,676 |
| XolairOmalizumab | 17 | $44,073 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $9,927 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,001 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,005 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $4,743 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,733 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,646 |
| Montelukast Sodium | 52 | $678 |
| Fluticasone Propionate | 40 | $376 |
| Azelastine Hcl | 29 | $344 |
| Ammonium Lactate | 15 | $226 |
| Triamcinolone Acetonide | 20 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Fasenra, Symbicort | $271 | $235,59260 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta | $126,010 | $24,93360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 allergy providers in New York.
Other allergy in Bronx
- Kishore AhujaBronx$3K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
- Alissa McInerneyAstoria$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.